For rheumatoid arthritis; osteoarthritis; low back pain; acute musculo-skeletal disorders and trauma such as periarthritis (especially frozen shoulder), tendinitis, tenosynovitis, bursitis, sprains, strains and dislocations; relief of pain in fractures; ankylosing spondylitis; acute gout; control of pain and inflammation in orthopaedic, dental and other minor surgery.
Allergan announced positive 3-month topline results from the second pivotal clinical trial of Bimatoprost SR, a first-in-class sustained-release, biodegradable implant...
This study will evaluate the intraocular pressure-lowering effect and safety of Bimatoprost SR compared with selective laser trabeculoplasty in patients with open-angle glaucoma or ocular hypertension who are not adequately managed with topical IOP-lowering medication.
Allergan announced positive 3-month topline results from the second pivotal clinical trial of bimatoprost SR , a first-in-class sustained-release, biodegradable...
This study evaluates the duration of intraocular pressure (IOP)-lowering effect and safety of as needed administrations of Bimatoprost sustained release (SR) in participants with open-angle glaucoma (OAG) or ocular hypertension (OHT) who are not adequately managed with topical IOP-lowering medication for reasons other than medication efficacy.
Takeda Pharmaceutical Company Limited and its partner, Zinfandel Pharmaceuticals, Inc. announced that the global Phase III TOMMORROW trial has been...
Allergan plc, has announced that the FDA has accepted the company's New Drug Application (NDA) for Bimatoprost Sustained-Release (SR). Bimatoprost...
• Reduction in the risk or delay of the onset of type 2 diabetes mellitus in adult, overweight patients with IGT* and/or IFG*, and/or increased HbA1C who are: - at high risk for developing overt type 2 diabetes mellitus (see section 5.1) and - still progressing towards type 2 diabetes mellitus despite implementation of intensive lifestyle change for 3 to 6 months. Treatment with Metabet SR/Sukkarto SR/Bolamyn SR/Metformin 750 mg Prolonged-Release Tablets must be based on a risk score incorporating appropriate measures of glycaemic control and including evidence of high cardiovascular risk (see section 5.1). Lifestyle modifications should be continued when metformin is initiated, unless the patient is unable to do so because of medical reasons. *IGT: Impaired Glucose Tolerance; IFG: Impaired Fasting Glucose • Treatment of type 2 diabetes mellitus in adults, particularly in overweight patients, when dietary management and exercise alone does not result in adequate glycaemic control. Metabet SR/Sukkarto SR/Bolamyn SR/Metformin 750 mg Prolonged-Release Tablets may be used as monotherapy or in combination with other oral antidiabetic agents, or with insulin.
Rhotard Morphine SR/ Morphgesic SR Tablets are indicated in adults for the prolonged relief of severe pain.